Quarterly report pursuant to Section 13 or 15(d)

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.22.2.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2022
Sep. 30, 2021
Sep. 30, 2022
Sep. 30, 2021
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS        
Revenue $ 0 $ 0 $ 0 $ 0
Operating Expenses        
General and administrative 2,023,937 1,763,060 5,377,185 5,061,820
Research and development 172,871 439,630 601,170 1,082,394
Total Operating Expenses 2,196,808 2,202,690 5,978,355 6,144,214
Other Operating Income        
Distribution from joint venture 0 0 0 110,000
Contributed services - research and development 71,335 288,884 278,189 459,997
Total Other Operating Income 71,335 288,884 278,189 569,997
Operating Loss (2,125,473) (1,913,806) (5,700,166) (5,574,217)
Other Income        
Interest income 87,943 1,551 110,465 6,183
Foreign currency transaction gain 0 0 0 33,694
Total Other Income 87,943 1,551 110,465 39,877
Net Loss Before Income Taxes (2,037,530) (1,912,255) (5,589,701) (5,534,340)
Income taxes 0 0 0 0
Net Loss (2,037,530) (1,912,255) (5,589,701) (5,534,340)
Accumulated preferred stock dividend 0 (135,091) 0 (399,838)
Deemed additional dividend on preferred stock dividend due to the beneficial conversion feature 0 (59,314) 0 (175,211)
Net Loss Attributable to Common Stockholders $ (2,037,530) $ (2,106,660) $ (5,589,701) $ (6,109,389)
Net Loss Per Common Share, Basic and Diluted $ (0.18) $ (0.31) $ (0.53) $ (0.92)
Weighted Average Number of Common Shares Outstanding 11,085,657 6,759,662 10,633,664 6,648,803